Principal Investigators: George Miller, MD
PureTech is a biotherapeutics company dedicated to changing the treatment paradigm for devastating diseases. The company has created a broad and deep pipeline through the expertise of its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders. This pipeline, which is being advanced both internally and through PureTech’s Founded Entities, comprises 26 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both U.S. FDA clearance and European marketing authorization and a third (KarXT) that will soon be filed for FDA approval, as of the most recent update by the company. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points based on its unique insights and technology platforms.